Effects of probiotic supplementation on post-infectious irritable bowel syndrome in rodent model

Ki-Bae Hong¹, Hyeyoung Seo², Joong-su Lee⁴ and Yooheon Park³*

Abstract

Background: Probiotics have been reported to be the active component used in the treatment of many functional gastrointestinal symptoms and syndromes. Lactobacillus and yeast culture are extensively used in probiotic supplements and traditional treatments for irritable bowel syndrome (IBS). The aim of this study was to investigate the effects of probiotic treatments (Lactobacillus acidophilus LA5, Bifidobacterium animalis subsp. lactis BB12 and Saccharomyces cerevisiae var. boulardii) on the behavioral response, targeted gene expression and pro-inflammatory cytokine levels of Pi (Post infectious)-IBS -induced mice.

Methods: Pathogen-free male C57L/B6 mice and the Trichinella-infected mice were used to measure the score of abdominal withdrawal reflex (AWR). To compare molecular, biological and biochemical evidences of given probiotics with normal and positive control groups in mice, we conducted quantitative reverse transcription polymerase chain reaction (RT-qPCR), western blotting, and cytokine analysis.

Results: Pi-IBS-induced immune response was confirmed that PAR-2 mRNA level was significantly increased by Trichinella infection (P < 0.05). The reduction of Pi-IBS symptoms through Trichinella infection and the effects of given probiotics were confirmed by a change in the protein levels of cytokines (P < 0.05). In addition, the administration of DW (Daewon) probiotics significantly decreased serum levels of IL-1 and IL-6 (P < 0.05).

Conclusions: We have demonstrated that the given probiotics decreased pro-inflammatory cytokine levels in both the control and Pi-IBS induced mice. Taken all the results together, the results support that DW probiotics has a potential as a probiotic medication for patient with IBS via regulating TNF-α and IL-6 protein levels and serum IL-1 and IL-6 levels.

Keywords: Probiotics, Irritable bowel syndrome, Trichinella, Abdominal withdrawal reflex

Background

Irritable bowel syndrome (IBS) is a type of functional gastrointestinal disorder and a major public health problem that occurs in 9–23% of the population across the world [1, 2]. In addition, IBS is defined as common disturbances of the bowel characterized by abdominal pain or discomfort existing alongside abdominal distension. The four main types are categorized by the presence or absence of different symptoms such as constipation predominant (IBS-C), diarrhea predominant (IBS-D), mixed subtype (IBS-M) and unclassified (IBS-U) [3]. A meta-analysis has found that there exists a 3- to 11-fold higher risk of IBS after an episode of gastroenteritis [4]. There is increasing evidence that changes in the gastrointestinal (GI) microbiota are involved in the outbreak of IBS. Recent research suggests that food sensitivity, post-infectious reactivity, brain-gut interactions, alterations in GI tract and fecal microbiota, and upregulation of the GI mucosal immune system are related to a role for the GI microbiota in the pathogenesis of IBS [5, 6].

IBS therapies can be divided into medical treatments (antidiarrheals, antispasmodics, fiber supplements, and laxative agents) and modifications of the microbiota (probiotics and antibiotics) [7]. The current medical treatment strategy for IBS is based on symptom type and severity, and these treatments provide temporary
symptom relief. Even though treatments have focused on over-the-counter medications to improve bowel habits, low costs, and safety, they have little impact on abdominal symptoms such as pain and bloating. Probiotics could alter the volume and/or composition of stool and gas or increase intestinal mucus secretion. These effects could influence intestinal handling of its contents and thus modulate symptoms such as constipation and diarrhea [8]. In clinical experience, the most efficacious utilization of probiotics in this field is the prevention of the post-infectious IBS (Pi-IBS) [9]

Pi-IBS is a common disease wherein IBS symptoms begin after acute gastroenteritis; this disease accounts for up to 4–30% of patients with bacterial gastroenteritis and seems to be a nonspecific response to infection [10]. Therefore, it is important to study the epidemiology and clinical features of Pi-IBS to understand the mechanisms that underlie it and to understand the treatments for this disorder. Pi-IBS is defined as the acute onset of new IBS symptoms in an individual who has not previously met the Rome criteria, immediately following an acute illness characterized by symptoms such as fever, vomiting, and alteration of stool form [11, 12]. In addition, Pi-IBS induced by Salmonella, Campylobacter and E. coli outbreaks, as well as bacteria and parasites are often used as Pi-IBS inducers in animal models. However, visceral hypersensitivity and alteration of motility and secretion, which are common characteristics of IBS, are weakly induced for Pi-IBS animal models infected by bacteria [13–15].

Experimental infection with the parasite, Trichinella, has been widely used to establish models for detecting the pathogenesis of intestinal dysfunction [16, 17]. A large number of studies have demonstrated that certain indicators, such as visceral hypersensitivity and the persistent dysfunction of the intestinal muscle, exist in mice infected with Trichinella spiralis [18]. Infection by Trichinella spiralis larvae induced changes in intestinal motility, visceral hyperalgesia, and intestinal mucus secretion [19]. These abnormal symptoms sustained after recovery from infection in a mouse model [20]. Accordingly, a T. spiralis-infected mouse is a suitable model of Pi-IBS.

In this study, Trichinella was used as a stimulant to induce Pi-IBS in a mouse model to evaluate the inflammatory response over the 4-week experiment to the intake of probiotic formulation. Thus, we have employed abdominal withdrawal reflex (AWR), quantitative reverse transcription polymerase chain reaction (RT-qPCR), western blot analysis, and cytokine analysis. The results suggest that probiotics formulated with two probiotic bacterial strains and yeast culture may be beneficial to human gastrointestinal health.

Methods
Animals
Four-week-old male C57L/B6 mice (15.5 ± 1.0 g) were obtained from Orient Bio Inc. (Gyeonggi-do, Republic of Korea). Animals were randomly divided into three groups, control group (control, n = 18), VSL3 group (VL, n = 18) and Daewon probiotic group (DW, n = 18). All animals were kept in a specific pathogen-free room at a temperature of 23 ± 2 °C in 50 ± 5% atmospheric humidity with 12-h light/dark cycles. The standard maintenance diet (Purina rodent chow) and tap water were freely provided in acrylic cages (Jeung do Bio & Plant Co., Ltd. Seoul, Korea) for 5 weeks and acclimatized for 1 week prior to use. Seven mice in each group were randomly selected for biological experiments and sacrificed by CO₂ inhalation. All experiments were approved by the Ethical Committee and performed according to the guidelines and regulations of the Animal Care committee, Dongguk University (Seoul, Republic of Korea).

Trichinella infection
Infective larvae were obtained from C57L/B6 mice infected with Trichinella at least 4 weeks in advance. The muscle containing encysted larvae were minced and digested in 1% pepsin A from porcine gastric mucosa (Sigma-Aldrich, St. Louis, MO, USA) and 1% HCl at 37 °C for 2 h. The isolated infective larvae were washed several times with PBS (Sigma-Aldrich). The Pi-IBS groups were infected by the oral administration of 250–300 larvae in 0.2 ml of solution, while the control group received the same volume of PBS.

Probiotics treatment
Formulated probiotics (DW) were provided by Daewon Pharm Co. Ltd. (Seoul, Korea). VSL#3 (Farccoderma Srl, Italy) were purchased from a local pharmacy. Briefly, DW was composed of two strains, namely, Lactobacillus acidophilus LA5 and Bifidobacterium animalis subsp. lactis BB12 and yeast culture (Saccharomyces cerevisiae var. boulardii). VSL#3 was composed of eight probiotic bacterial strains, (Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum subsp. longum, Bifidobacterium longum subsp. infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus delbrueckii subsp. bulgaricus). After 2 weeks of inflammation, sample was diluted and spread on Petri dishes using BL and MRS agar to count and confirm the number of probiotics each mouse in acrylic cages was administered with probiotics (0.2 ml of the solution of 5.0 × 10⁹ CFU/g probiotics and yeast) and placebo solution, respectively, between 10:00 and 11:00 in a specific pathogen-free room. In addition, individual treatments were not revealed to the observers for oral administration [21].
AWR (abdominal withdrawal reflex)
Mice were anesthetized with ether, and a distension balloon catheter (6-Fr, 2 mm external diameter) was placed in the descending colon of mildly sedated mice. After waking up and adapting for 20 min, each 10-s distention was followed by a 20-s resting period. Each level of distention (0, 0.35, 0.5 ml) was repeated two times, and the balloon was deflated and withdrawn after measuring AWR. The visceral sensory responses to rectal distention was quantified by scoring the AWR, as described in elsewhere [22].

mRNA levels
RT-qPCR was used to measure epithelial-derived mRNA of protease-activated receptor-2 (PAR-2). Total RNA from intestinal tissues was isolated using the TRIzol reagent (Invitrogen, CA, USA) according to the manufacturer’s protocol. The concentration of total RNA was determined photometrically using a NanoQuant plate (Tecan Infinite 2000, Männedorf, Switzerland). Quality controlled RNA samples were treated with RQ1 RNase-free DNase I (Promega, WI, USA) and 1 μg of total RNA was reverse transcribed using SuperScript III Reverse Transcriptase (Invitrogen). RT-qPCR was performed on the generated cDNA using the power Taqman PCR Master Mix kit (Applied Biosystems, CA, USA). Quantitative analysis was carried out using StepOne plus Software V. 2.0 (Applied Biosystems) and results were normalized to a validated control gene, GAPDH, using the ΔΔCt method [23].

Western blotting analysis
Western blotting was performed to measure protein expression levels of cytokines by homogenizing intestinal cells in RIPA (Radio Immuno Precipitation Assay) buffer with protease and phosphatase inhibitor cocktail. Homogenized samples were then centrifuged at 10,000 rpm for 15 min. Protein concentrations in the supernatant of homogenized samples were then measured using a Bradford assay. To denature the protein, loading buffer with the anionic denaturing detergent, sodium dodecyl sulfate (SDS), was used. After being diluted with loading buffer, the mixture was heated at 95 °C for 10 min. Depending on the molecular weights, 40 μg of protein lysate derived from intestinal samples were loaded onto 10% SDS-PAGE (Sodium Dodecyl Sulfate Polyacrylamide Gel electrophoresis) gel. Proteins were then transferred to nitrocellulose membranes and detected with a specific antibody against tumor necrosis factor-alpha (TNF-α; ab6671) and interleukin 6 (IL-6; ab208113) using the ChemiDoc™ imaging systems (Bio-Rad, Hercules, CA).

Cytokine analysis
The blood serum samples were centrifuged, and then, the serum was separated and stored at −80 °C. IL-1, IL-6 and TNF-α in serum were analyzed by quantification with MILLIPLEX® Multiplex assays according to the manufacturer’s instructions.

Statistical analysis
Statistical analysis was determined using GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA, USA). All of the data are expressed as the mean ± standard deviation (SD). Differences between groups were evaluated by one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparison test at a level of significance of P < 0.05. Single, double, and triple asterisk(s) were assigned to the experimental groups when they were significantly different from the control group at P < 0.05, P < 0.01 and P < 0.005, respectively.

Results
Effects on AWR score
The changes in AWR scores, according to Trichinella infection and probiotic administration during the 4-week period, are presented in Table 1. The AWR score for all experimental groups during the recording period showed an increase in volume dependence by CRD (0.25–0.5 ml water). After infection, 1-week PI groups showed a significant increase of AWR scores for distention (0.35–0.5 ml) (P < 0.05). In the comparison of 4-week PI control group, continuous probiotics administration significantly reduced both allodynia and hyperalgesia at 0.25–0.5 ml of CRD (P < 0.05). These results suggest that a decrease in visceral hypersensitivity was noted in two strains, Lactobacillus and yeast culture. Also, Trichinella infection and probiotic administration did not affect body weight, food intake, and drink volume (data not shown).

Table 1 Effect of given probiotics on abdominal withdrawal reflex (AWR) to colorectal distention (CRD)

| Groups         | N  | Volume of colon distention |
|----------------|----|---------------------------|
|                |    | 0.20 ml | 0.30 ml | 0.40 ml |
| 1 weeks        |    |          |         |         |
| Uninfected     |    |          |         |         |
| Control        | 9  | 0.22 ± 0.34 | 1.18 ± 0.42 | 2.7 ± 0.33 |
| VL             | 9  | 0.23 ± 0.37 | 1.13 ± 0.31 | 2.4 ± 0.35 |
| DW             | 9  | 0.21 ± 0.33 | 1.09 ± 0.41 | 2.6 ± 0.39 |
| Infected       |    |          |         |         |
| Control        | 9  | 0.53 ± 0.35 | 1.82 ± 0.34 | 3.3 ± 0.38 |
| VL             | 9  | 0.54 ± 0.33 | 1.84 ± 0.38 | 3.4 ± 0.24 |
| DW             | 9  | 0.48 ± 0.42 | 1.79 ± 0.39 | 3.3 ± 0.39 |
| 4 weeks        |    |          |         |         |
| Uninfected     |    |          |         |         |
| Control        | 9  | 0.22 ± 0.22 | 1.21 ± 0.27 | 2.5 ± 0.29 |
| VL             | 9  | 0.21 ± 0.33 | 1.19 ± 0.31 | 2.6 ± 0.26 |
| DW             | 9  | 0.21 ± 0.29 | 1.16 ± 0.28 | 2.4 ± 0.31 |
| Infected       |    |          |         |         |
| Control        | 9  | 0.3 ± 0.42 | 2.29 ± 0.24 | 3.89 ± 0.22 |
| VL             | 9  | 0.3 ± 0.30 | 1.71 ± 0.32 | 2.68 ± 0.40 |
| DW             | 9  | 0.3 ± 0.34 | 1.52 ± 0.37 | 2.48 ± 0.29 |
Effects on PAR-2 transcription
To examine whether the development of Pi-IBS through *Trichinella* infection and the effects of given probiotics caused a transcriptional process, the levels of mRNA for PAR-2 was determined (Fig. 1). Before *Trichinella* infection, the mRNA level of PAR-2 was not significantly decreased by both probiotic treatments and PAR-2 levels in infected animals were significantly increased in the control group when compared to the pre-infection control group (1.5 folds, \( P < 0.05 \)) (Fig. 1a and b). In the infected animals, transcript levels for the PAR-2 in the VL group were significantly higher than the control group (Fig. 1a, \( P < 0.01 \)), but a probiotic treatment of DW significantly decreased PAR-2 mRNA level compared to control and VL groups (Fig. 1b, \( P < 0.01 \) and \( P < 0.001 \)).

Effects on TNF-\( \alpha \) and IL-6 protein expression
The effects of DW treatment on intestinal TNF-\( \alpha \) and IL-6 protein expression, induced by *Trichinella* infection, are shown in Fig. 2. The administration of all treatments had no effect on the levels of intestinal TNF-\( \alpha \) compared to the control group. After *Trichinella* infection, the control group and VL group showed a significant increase in intestinal TNF-\( \alpha \) levels, and these results showed that the increase in the pro-inflammatory cytokine probably resulted in enhanced acute mucosal inflammation by *Trichinella*. Intestinal TNF-\( \alpha \) levels in the DW group was 1.34-fold lower compared to the control and VL groups (\( P < 0.05 \)).

Effects on serum cytokine levels
As shown in Figs. 3, 4 and 5, the levels of pro-inflammatory cytokines (TNF-\( \alpha \), IL-1, and IL-6) in the serum were measured. VL administration had no effect on the levels of TNF-\( \alpha \), IL-1, and IL-6 in the serum of uninfected group. DW administration caused significant reductions in TNF-\( \alpha \) and IL-1 levels of uninfected mice compared to those in the control group (TNF-\( \alpha \) and IL-1: \( P < 0.05 \)) and VL group (TNF-\( \alpha \): \( P < 0.01 \)). After *Trichinella* infection, VL group showed a significant increase in TNF-\( \alpha \), IL-1, and IL-6 levels in the serum (\( P < 0.05 \)), and these results indicate that activated immune cells continue to release inflammatory cytokines after an infection. Although *Trichinella* infection to induce the Pi-IBS model, the serum cytokine levels of DW receiving mice were significantly reduced in comparison to the control and VL groups (\( P < 0.05 \)).

Discussion
Previous studies recognize that probiotics have health-beneficial effects on gut motility, immune modulation, pathogen exclusion, and epithelial barrier function. Additionally, probiotics are defined as live microorganisms which when administered in adequate amounts confer a health benefit on the host with gastrointestinal therapeutic potential, and they have been used in *Clostridium difficile* colitis, traveler’s diarrhea, antibiotic-associated diarrhea, inflammatory bowel disease, and IBS [21, 24]. Although IBS has a multifactorial etiology, and the exact mechanisms of how probiotics elicit the reductions of IBS symptoms are unknown, appropriate biomarkers are used for the evaluation of selected probiotic strains. The mechanisms of these health effects are also being revealed through in vitro and animal studies, which can be expected to lead to selection criteria for probiotics.

In the present study, we demonstrated the effects of given probiotics on colorectal distention through AWR assay (Table 1). Although approved live bacterial strains show great efficacy to gut microbiota, barrier function and the intracolonic short chain fatty acids (SCFAs), each strain is rarely used along for the treatment of IBS [25, 26]. Wang H et al. demonstrated that the groups of different probiotics and mixture (*Bifidobacterium longum*, *Lactobacillus acidophilus* and *Enterococcus faecalis*) markedly decreased AWR scores and contractile response, compared to PI-IBS mice [27]. Additionally, flatulence scores and retards colonic transit of patients

![Fig. 1 Intestinal mRNA levels of PAR-2 in Pi-IBS induced mice treated with or without probiotic treatments. VL: VSL3; DW: Daewon. Values are Mean ± SD (n = 9). Different symbols indicate significant difference at **\( p < 0.01 \) and ***\( p < 0.001 \).](attachment:image.png)
with Rome II IBS were significantly reduced through the treatment of a composite probiotic (VSL# 3) [28].

Using RT-qPCR analysis, we studied the effects of given probiotics on target gene expression levels (Fig. 1). PARs belong to the family of G protein-coupled receptors (GPCRs) and are known to be associated with inflammatory conditions and tumor progression in previous studies. Additionally, PARs are expressed throughout the GI tract on several cell types, and activation of PAR-2 has been found on both the apical and basolateral side of colonic epithelial cells [29]. PAR-2 activation has been reported to cause the release of pro-inflammatory cytokines (e.g., IL-1β, IL-6, IL-8, TNF-α) and is important in the pathogenesis of organic and Functional GI disorders [30, 31]. In addition, Nébot-Vivinus M et al. demonstrated the relationship of probiotic dietary supplement (Lactibiane Tolerance®; consisting of L. acidophilus, L. plantarum, L. salivarius, and two stains of B. lactis) and epithelial barrier impairment with visceral hypersensitivity by IBS colonic fluid in C57BL/6 mice [32].

We also investigated the effects of given probiotics on the levels of pro-inflammatory cytokines, TNF-α and IL-6 (Fig. 2). Although cytokines are important signal
transducers in the immune system, they regulate nerve function. Bertiaux-Vandaële N et al. announced that TNF-α causes marked sensitization to mechanical stimulation mediated by the interaction between TNFR1 and transient receptor potential A1 in IBS patients [33]. In addition, IL-6 is known to be a non-specific pro-inflammatory cytokine that influences adrenal stress response and gastric motility. Comparison studies of the genotypes and cytokines have shown that changes in IL-6 levels also related an acquired phenomenon and other potential gene polymorphisms [34].

Moreover, mice in probiotic treated groups showed significant regulations in serum levels of IL-1 and IL-6, compared to the mice in the control group (Figs. 3, 4, 5). Levels of IL-1β, TNF-α, and IL-6 have been found to be positively correlated with IBS symptoms in blood cytokine profiles in IBS patients. Wang IK et al. investigated the effect of probiotics administration on serum levels of cytokines and endotoxins in peritoneal dialysis (PD) patients and the results showed that levels of serum TNF-α, IL-5, IL-6, and endotoxin significantly decreased after six months of treatment [35]. Additionally, Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri significantly downregulated urinary TNF-α in the spinal cord injury patient [35]. In addition, levels of TNF-α, IL-1β, and IL-6 in peripheral blood mononuclear cells are correlated with symptom severity of IBS-D, including the intensity and frequency of pain and pain-related symptoms [36]. Shadnoush M et al. demonstrated that oral intake of 250 g of Bifidobacterium and Lactobacillus in the form of probiotic yogurt regulates the serum levels of IL-1β, IL-6, IL-10 and C-reactive protein (CRP) [37].

Conclusion
In conclusion, we suggest that the Pi-IBS experimental approach can be used to assess the therapeutic potential of probiotic strains and assist IBS patients, based on the results. The effects of DW probiotics were associated with regulation of the protein levels of pro-inflammatory cytokines, TNF-α and IL-6, leading to the normalization of epithelial barrier integrity, and modulation of serum cytokine levels through a cross-talk between treatment and microbiota. The outcomes in this study are expected to provide behavioral, biochemical and molecular biological evidence for further understanding of probiotic strains and its impact on IBS symptoms.
Abbreviations
AWR: Abdominal withdrawal reflex; CRP: C-reactive protein; FGIE: Functional gastrointestinal disorder; GPCR: G protein-coupled receptors; IBS: Irritable bowel syndrome; IL: Interleukin; PAR-2: Protease-activated receptor-2; PD: Pentoneal dialysis; Pi-IBS: Post infectious irritable bowel syndrome; SCFA: Short chain fatty acid; TNF-α: Tumor necrosis factor-alpha

Acknowledgments
Not applicable.

Authors’ contributions
This topic was designed by YP and JL; KH, HS carried out molecular studies, the research process, data analysis and writing paper. All authors read and approved the final manuscript.

Funding
The experimental design, the preparation of sample, the analysis of animals and the interpretation of results data for this research was mainly supported by Daewon Pharm Co., Ltd. (S-2017-ED766-00002).

Availability of data and materials
The dataset generated during the present study is available upon reasonable request to the author (Prof. Yooheon Park).

 Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Biological Sciences and Environmental Sciences Program, Southern Illinois University-Edwardsville, Edwardsville, IL 62026, USA.
2Department of Biomedical and Life Science, Graduation School, Korea University, Seoul 02841, Republic of Korea. 3Department of Food Science and Biotechnology, Dongguk University, Goyang 10326, Republic of Korea. 4Probiotics center, Division of Healthcare, Daewon Pharmaceutical Company, 520 Cheonho-dae-ro, Sungdong-gu, Seoul, Republic of Korea.

Received: 21 May 2018 Accepted: 23 July 2019
Published online: 31 July 2019

References
1. Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther. 2014;40:1023–34.
2. Saha L. Irritable bowel syndrome. Pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol. 2014;20:759–73.
3. Yao Y, Yang YS, Cui LH, Zhao KB, Zhang ZH, Peng LH, et al. Subtypes of irritable bowel syndrome on Rome III criteria: a multicenter study. J Gastroenterol Hepatol. 2012;27:769–70.
4. Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome-a meta-analysis. Am J Gastroenterol. 2006;101:1894–9.
5. Occhipinti K, Smith JW. Irritable bowel syndrome: a review and update. Clin Colon Rectal Surg. 2012;25:46–52.
6. Parkes GC, Sanderson JD, Whelan K. Treating irritable bowel syndrome with probiotics: the evidence. Proc Nutr Soc. 2010;69:187–94.
7. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015;313:949–58.
8. Camilleri M. Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy. J Clin Gastroenterol. 2006;40:264–9.
9. Cuomo R, Savarese MF, Gargano R. Almost all irritable bowel syndromes are post-infectious and respond to probiotics: consensus issues. Dig Dis. 2007;3:241–4.
10. Spiller R, Campbell E. Post-infectious irritable bowel syndrome. Curr Opin Gastroenterol. 2006;22:13–7.
11. Strader BD, Isaias UA Jr. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011;140:1756–67.
12. Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol. 2003;98:1578–83.
13. Schirweill-Kuinkle J, Enck P, Zeddler C, Krieg M, Polster AV, Klosterhalfen S, Autenrieb EK, Zippel S, Frick JS. Postinfectious irritable bowel syndrome: follow-up of a patient cohort of confirmed cases of bacterial infection with Salmonella or campylobacter. Neurogastroenterol Motil. 2011;1;3:e47–98.
14. Wang LH, Fang HC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut. 2004;53:1096–101.
15. Qin HY, Wu JC, Tong XD, Sung JJ, Xu HX, Bian ZX. Systematic review of animal models of post-infectious/post-inflammatory irritable bowel syndrome. J Gastroenterol. 2011;46:164–74.
16. Tanovic A, Fernandez E, Jimenez M. Alterations in intestinal contractility during inflammation are caused by both smooth muscle damage and specific receptor-mediated mechanisms. Croat Med J. 2006;47:318–26.
17. Longet D, Vergara P. In vivo changes in the intestinal reflexes and the response to CCK in the inflamed small intestine of the rat. J Am Physiol Gastroint Liver Physiol. 2000;279:G543–51.
18. Vallance BA, Croitoru K, Collins SM. T lymphocyte-dependent and -independent intestinal smooth muscle dysfunction in the T. spiralis-infected mouse. Am J Physiol. 1998;275:G157–65.
19. Bercik P, Wang L, Verdu EF, Mao YK, Bienenbassett H, Khan WJ, et al. Visceral hyperalgesia and intestinal dysmotility in a mouse model of postinfective gut dysfunction. Gastroenterology. 2004;127:179–87.
20. Long Y, Wang W, Wang H, Hao L, Qian W, Hou X. Characteristics of intestinal lamina propria dendritic cells in a mouse model of postinfectious irritable bowel syndrome. J Gastroenterol Hepatol. 2012;27:935–44.
21. Aagotn G, Graham DB, Borum M, Doman DB. Probiotic therapy for irritable bowel syndrome. Gastroenterol Hepatol (NY). 2010;6:39–44.
22. QD, BI WM. Effects of electroacupuncture on expression of c-fos protein in the spinal dorsal horn of rats with chronic visceral hyperalgesia. Zhong Xi Yi Jie He Xue Bao. 2012;10:1490–6.
23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2–ΔΔCT method. Methods. 2001;25:402–8.
24. Hill C, Guimer F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME. Expert consensus document. The international scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11:505–14.
25. Singh H, Arioli S, Wang A, Villa CR, Jahanri R, Song YS, et al. Impact of Bifidobacterium bifidum MMiBb75 on mouse intestinal microorganisms. FEMS Microbiol Ecol. 2013;83:369–75.
26. Vanderhoof JA. Probiotics: future directions. Am J Clin Nutr. 2001;73:1125–55.
27. Wang H, Gong J, Wang W, Long Y, Fu X, Fu Y, et al. Are there any different effects of Bifidobacterium, Lactobacillus and Streptococcus on intestinal sensation, barrier function and intestinal immunity in PhIBs mouse model? PLoS One. 2014;9:e90153.
28. Kim HI, Vazquez Roque MJ, Camilleri M, Stephens D, Burton DD, Baxter K, et al. A randomized controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil. 2005;17:687–96.
29. Kong W, McConagule K, Khiltn LM, Hollenberg MD, Payan DG, Bohm SK, et al. Luminal trypsin may regulate enterocytes through proteinase-activated receptor 2. Proc Natl Acad Sci U S A. 1997;94:8884–9.
30. Johannson U, Lawson C, Babare M, Syndercombe-Court D, Newland AC, Howells GL, et al. Human peripheral blood monocytes express protease receptor-2 and respond to receptor activation by production of IL-6, IL-8, and IL-11beta. J Leukoc Biol. 2005;78:967–75.
31. Hjortoe GM, Petersen LC, Albrektsen T, Sorensen BB, Norby PL, Mandal SK, et al. Prebiotics consensus statement on the scope and appropriate use of the term prebiotic. World J Gastroenterol. 2012;18:506–14.
32. Howells GL, et al. Human peripheral blood monocytes express protease receptor-2 and respond to receptor activation by production of IL-6, IL-8, and IL-11beta. J Leukoc Biol. 2005;78:967–75.
33. Hjortoe GM, Petersen LC, Albrektsen T, Sorensen BB, Norby PL, Mandal SK, et al. Prebiotics consensus statement on the scope and appropriate use of the term prebiotic. World J Gastroenterol. 2012;18:506–14.
33. Bertiaux-Vandaele N, Youmba SB, Belmonte L, Leclaire S, Antonietti M, Gourcerol G, et al. The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype. Am J Gastroenterol. 2011; 106(12):2165–73.

34. Bashashati M, Farvid M, Sarosiek I. Interleukin-6 in irritable bowel syndrome: a systematic review and meta-analysis of IL-6 (−G174C) and circulating IL-6 levels. Cytokine. 2017;99:132–8.

35. Wang IK, Wu YY, Yang YF, Ting IW, Lin CC, Yen TH, et al. The effect of probiotics on serum levels of cytokines and endotoxin in peritoneal dialysis patients: a randomised, double-blind, placebo-controlled trial. Benefic Microbes. 2015;6:423–30.

36. Hughes PA, Zola H, Penttila IA, Blackshaw LA, Andrews JM, Krumbiegel D. Immune activation in irritable bowel syndrome: can neuroimmune interactions explain symptoms? Am J Gastroenterol. 2013;108:1066–74.

37. Wong C, Ustunol Z. Mode of inactivation of probiotic bacteria affects interleukin 6 and interleukin 8 production in human intestinal epithelial-like Caco-2 cells. J Food Prot. 2006;69:2285–8.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.